Company: BFRG
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023496
Chunk: 32

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 32
---
 optimization with a Phase III oncology
company focused on novel chemotherapeutic treatments for rare cancers in the third quarter of 2025. We have also acquired the rights
to a series of preclinical and early clinical drug assets from universities, as well as entered into a strategic collaboration with a
world-renowned research institution to create a HSV1 viral therapeutic platform to engineer immunotherapies for a variety of diseases.
We have signed exclusive worldwide license agreements with Johns Hopkins University (“JHU”) for a cancer drug that targets
glioblastoma (brain cancer), pancreatic cancer, and others. We have also signed an exclusive worldwide license from George Washington
University for another cancer drug that targets hepatocellular carcinoma (liver cancer) and other liver diseases. In addition, we signed
three-year strategic data and commercialization agreements with the Lieber Institute for Brain Development (“LIBD”) whom
we believe has a repository of the largest collection of postmortem brains in the world, including molecular, clinical, and other data.
The objective of this collaboration with LIBD is for the Company to analyze these rich data sets using its proprietary AI/ML tools and
models and then go to market with the discoveries with the ultimate goal of securing revenue generating strategic partnership deals with
biopharmaceutical companies. We intend to secure the rights to other proprietary data sets and repeat this strategy. Additionally, we
intend to gain access to later-stage clinical assets through partnerships or the acquisition of rights to failed therapeutic candidates
for drug rescue. In certain circumstances, we intend to conduct late-stage clinical trials in an effort to rescue therapeutic assets
that previously failed. In these cases, there will be a requirement for drug supply and regulatory services to conduct clinical trials.
The success of our clinical development programs will require finding partners to support the clinical development, adequate availability
of raw materials and drug product for our research and development and clinical trials, and, in some cases, may also require the establishment
of third-party arrangements to obtain finished drug product that is manufactured appropriately under good manufacturing practices, and
packaged for clinical use or sale. Since we are a company focused on using our AI/ML technology to advance medicines, any clinical development
programs will also require, in all cases, partners and the establishment of third-party relationships for execution and completion of
clinical trials.

Since
completing our initial public offering in February 2023 (the “IPO”), aided by the receipt of the IPO proceeds in addition
to the proceeds from our